### **Title**

1

- 2 Initial experience in Mexico with convalescent plasma in COVID-19 patients with
- 3 severe respiratory failure, a retrospective case series
- 5 **Authors:**
- 6 Michel F. Martinez-Resendez<sup>1</sup>, Fernando Castilleja-Leal<sup>1</sup>, Alejandro Torres-Quintanilla<sup>1</sup>,
- 7 Augusto Rojas-Martinez<sup>1</sup>, Gerardo Garcia-Rivas<sup>1</sup>, Rocio Ortiz-Lopez<sup>1</sup>, Victor Trevino<sup>1</sup>,
- 8 Reynaldo Lara-Medrano<sup>1</sup>, Hiram Villanueva-Lozano<sup>1</sup>, Teresa Ramirez-Elizondo<sup>1</sup>, Victor
- 9 M. Sanchez-Nava<sup>1</sup>, Francisco Moreno-Hoyos<sup>1</sup>, Alfonso Martinez-Thomae<sup>1</sup>, Martin
- 10 Hernández-Torre<sup>1</sup>, Carlos Diaz-Olachea<sup>1</sup>, Servando Cardona-Huerta<sup>1</sup>, Sylvia de la Rosa-
- 11 Pacheco<sup>1</sup>, Carlos Diaz-Garza<sup>1</sup>, Paola Reynoso-Lobo<sup>1</sup>, Alma R. Marroquin-Escamilla<sup>1</sup>,
- 12 Jessica G. Herrera-Gamboa<sup>1</sup>, Fatima M. Alvarado-Monroy<sup>1</sup>, Claudia D. Aguayo-Millan<sup>1</sup>,
- 13 Francisco F. Villegas-Macedo<sup>1</sup>, Jesus Efrain Flores-Osorio<sup>1</sup>, Daniel Davila-Gonzalez<sup>1</sup>,
- 14 María Eugenia Diaz-Sanchez<sup>1</sup>, Guillermo Torre-Amione<sup>1,\*</sup>.
- 15 la Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud,
- Monterrey, Mexico.
- \*Corresponding author: Guillermo Torre-Amione. Tecnologico de Monterrey, Escuela
- de Medicina y Ciencias de la Salud, Monterrey, Mexico, gtorre@tecsalud.mx

### **Abstract**

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

**Introduction:** Hospital mortality due to COVID-19 in Mexico is high (32%) and as of today, effective treatment options are limited. More effective treatments that shorten hospital stay and reduce mortality are needed. Initial reports for the use of convalescent plasma (CP) therapy for COVID-19 appear promising. We describe a case series of eight patients with impending respiratory failure, who underwent CP therapy. Methods: Six male and two female (ages 31 to 79) patients that were admitted to the intensive-care unit for severe COVID-19 were transfused with two doses of CP (250 mL per dose, anti-SARS-CoV-2 IgG titers > 1:100). Donors were six SARS-CoV-2 infected males who remained asymptomatic for > 7 days and were negative for two nasopharyngeal RT-PCR tests. Clinical characteristics, inflammatory and cellular injury markers, chest Xray findings and viral loads were analyzed before and after CP administration. Viral load association to disease severity was further analyzed on a separate cohort of asymptomatic vs hospitalized patients with COVID-19. **Results:** Eight patients with respiratory failure were successfully discharged with a median length of stay of 22.5 (IQR 18.25-29.00). After CP therapy, we observed a reduction of Creactive protein (CRP) (median, 22.80 mg/dL vs. 1.63 mg/dL), and of procalcitonin (median, 0.27 ng/mL vs. 0.13 ng/mL). High-Sensitivity Cardiac Troponin I (hs-cTnI), Brain Natriuretic Peptide (BNP) and Lactate Dehydrogenase (LDH) were lower, and a mild reduction of pulmonary infiltrates by chest X-ray was observed. Lastly, a reduction of viral load was after CP therapy was found. (log, median [IQR], 1.2 [0.70-2.20] vs. 0.25 [0.00-1.78]). We observed no adverse effects.

- 41 Conclusions: CP could potentially be an effective therapeutic option for patients with
- 42 severe COVID-19. Clinical benefit needs to be studied further through randomized
- 43 controlled trials.

45 **Keywords:** COVID-19, SARS-CoV-2, convalescent plasma, Mexico, case series

# Introduction

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

As the COVID-19 pandemic has progressed, it has shifted epicenter into the Americas. As of June 9, 4 of the 10 nations with the highest number of new cases are Latin American countries: Brazil, Peru, Chile and Mexico (1). Complicating things further, Mexico has seen an increasing hospital mortality, which stands now at 32% (2). Hospital saturation must be an involved factor explaining said high mortality, as Mexico reports the lowest number of hospital beds per 1,000 habitants among the OECD member countries, as per the latest data (3). Certainly, therapies that reduce mortality and shorten hospital stay are needed globally. As there are few therapeutic options, such as antivirals and monoclonal antibodies, and their potential efficacy is still being determined, convalescent plasma (CP) could represent a lower cost alternative (4). This last property could be particularly helpful for developing countries, if CP is proven to be effective. As CP has been used for more than a century for the treatment of different infectious diseases, especially during epidemics or pandemics such as SARS, influenza or Ebola virus, there is vast experience with this safe therapeutic alternative. Nonetheless, the mechanisms of action may vary for every virus for which it is used, and are still being revisited (5). CP has been successfully used in the treatment of SARS and MERS. Moreover, recent independent studies of CP therapy in patients with COVID-19 provide evidence for its use (6–8). In this paper we describe our initial experience with the use of CP in a case series of patients with COVID-19 with impending respiratory failure.

# Materials and methods

### **Patients**

67

68

69 Eight critically ill patients with COVID-19 that were admitted to the COVID-19 Unit at 70 Hospital San José TecSalud in Monterrey, Mexico, from March 10 to May 21, 2020, 71 received CP therapy. All patients had impending respiratory failure associated with 72 COVID-19 and were confirmed by RT-PCR testing before received treatment with CP. 73 ABO and Rh blood types of the patients were determined for potential compatibility with 74 the CP donor, and each subject received two transfusions of 250 mL of CP separated by 24 75 hours. Plasma was infused at 20 mL/min and monitored for 15 minutes after the infusion 76 and no premedication was used. All patients were previously initiated on local established 77 and protocolized therapy including antiviral agents, moreover the patients received 78 supportive care such as antibiotic treatment, antipyretics, analgesics, fluids and nutrition. 79 This study was approved by the Clinical Research Ethics Committee of the School of 80 Medicine at Tecnológico de Monterrey (P000353-COVID-19 TecSalud-CEIC-CR001). 81 Written informed consent was obtained from all patients. All patients received CP 82 treatment under compassionate use due to impending respiratory failure after case review 83 by the hospital bioethics committee.

#### **Donors**

84

85

86

87

88

We obtained CP from 6 male donors who were between the ages of 22 and 57 years. The donors had recovered from SARS-CoV-2 infection with at least 7 days without any symptoms and 2 negative RT-PCR tests. They were invited to donate their plasma after

written informed consent was obtained. In addition, the donors were screened to rule out hepatitis B virus, hepatitis C virus, Epstein Barr virus, HIV, *Brucella abortus*, *Trypanosoma cruzi* and syphilis infection at the time of blood donation. Donors showed anti-SARS-CoV-2 IgG antibody titers higher than 1:100 as determined by ELISA. Written informed consent was obtained and ABO-compatible plasma samples were obtained by apheresis. Depending on bodyweight, 600-800 mL were collected and divided into 250 mL aliquots. A first dose of CP was transfused to recipients at baseline and a second dose 24 hours afterwards.

#### **Clinical information**

Data from patients was obtained from medical records. Retrieved data included: demographics, symptoms, days from symptom onset to admission, length of stay, pharmacologic therapy, type and duration of ventilator support, vital signs (temperature, heart rate, respiratory rate, SaO<sub>2</sub>/FiO<sub>2</sub>, and blood pressure), severity scores [Sequential Organ Failure Assessment (GOFA), the quick Sequential Organ Failure Assessment (qSOFA), the Pneumonia Severity Index (PSI), the Confusion, blood Urea nitrogen, Respiratory rate, Blood pressure, age 65 score (CURB-65)], laboratory data [complete blood count, blood chemistry, liver function testing, cultures, SARS-CoV-2 transcript copies, inflammatory markers like C-reactive protein (CRP), procalcitonin, troponin, brain natriuretic peptide (BNP), lactate dehydrogenase (LDH), D-dimer, ferritin and interleukin-6 (IL-6)], chest X-Ray or CT-scan findings, and clinical events and outcomes (ARDS, bacterial pneumonia, multiple organ dysfunction syndrome and death). Inflammation markers were taken at admission, before each dose of CP and at 48 hours follow-up.

### Patient cohort for viral load control group

- Discarded samples from clinical laboratory were obtained to determine viral load in a group
- of asymptomatic outpatients (n=23) as well as in hospitalized COVID-19 patients. (n=21).

### Chest X-ray pulmonary infiltrates severity scoring

- All patients were evaluated for pulmonary infiltrates severity on chest X-ray as previously
- 118 reported (9). Briefly, each lung is assigned a score of 0-4 depending on the extent of
- consolidation or ground-glass opacities as follows: 0 = no involvement; 1 = <25%; 2 = 25-
- 50%; 3 = 50-75%; 4 = >75% involvement. The final score corresponds to the sum of the
- scores for each lung.

112

113

115

116

122

123

#### **RT-PCR Test**

- We used the Applied Biosystems<sup>TM</sup> TaqMan<sup>TM</sup> 2019-nCoV Assay Kit v1 (Cat. No.
- 125 A47532) for the qualitative detection and characterization of 2019-nCoV RNA. The kit
- includes three PCR assays that target viral genes, and one positive control assay that targets
- the Human RNase P RPPH1 gene. The reactions were performed according to
- manufacturer instructions. Briefly, the 25uL reactions for each 2019-nCoV assay include
- Master Mix 6.25uL, 2019-nCoV assay primers and probes per gene 1.25 uL, RNAse P
- 130 1.25uL, RT-PCR grade water 11.25uL, and testing sample 5uL. The testing sample could
- be a biological specimen from a patient, positive control (A47533), or water as non-
- template control. The cycling conditions were 2 min @ 25°C, 10 min @ 50°C, 2 min @
- 95°C, and 40-45 cycles of 3 sec @ 95°C and 30 sec @ 60°C. This PCR program was run in

a QuantStudio 5 Real-Time PCR system (ThermoFisher). Automatic threshold detection was used as instructed. A sample is positive if at least two of the three COVID-19 genes amplifications were detected above threshold before cycle 38. A negative result is given if no amplification of the three COVID-19 genes was observed. An invalid result is given if any of the three amplifications of RNAse P was not observed before cycle 38. If otherwise, an indeterminate result is given. If an indeterminate result is observed, the set of reactions for the sample is repeated and the result is reported. To estimate the viral load, we used a dilution series of the positive control (A47533) included in each PCR plate and used the regression curve to estimate the minimum and maximum viral load from the curves of each of the three viral genes. The regression was estimated automatically by the Design & Analysis Software Release Version 2.3.0 obtained from Thermo Fisher Scientific web site.

## **Serology Test**

Antibody titers for IgG and IgM antibodies against SARS-CoV-2 were obtained using the EDI<sup>TM</sup> Novel Coronavirus COVID-19 IgG and IgM ELISA Kits (Epitope Diagnostics, San Diego, CA) following manufacturer instructions. Briefly, serum samples were diluted (1:50 and 1:100) and incubated in the microtiter wells of a microplate that is coated with COVID recombinant full length nucleocapsid protein (SARS-CoV-2 antigen). Positive and negative control calibrators were included. Results were reported as positive or negative at the specific dilution (1:50 or 1:100 for IgG and 1:10 for IgM) based on the optical density (OD). The cutoffs were calculated considering the average value of the absorbance of the negative control (xNC). The cutoffs for IgG antibodies were calculated using the following formulas: Positive cutoff =  $1.1 \times (xNC + 0.18)$  and negative cutoff =  $0.9 \times (xNC + 0.18)$ .

Cutoff values < 0.284 were considered negative, > 0.284 to < 0.3476 were considered borderline, and > 0.3476 were considered positive, per manufacturer instructions. The cutoffs for IgM antibodies were calculated using the following formulas: Positive cutoff = 1.1 X (xNC + 0.10) and negative cutoff = 0.9 x (xNC + 0.10). Cutoff values < 0.218 were considered negative, > 0.218 to < 0.265 were considered borderline, and > 0.265 were considered positive, per manufacturer instructions.

### **Statistical Analysis**

Frequencies and percentages are used for categorical data, and medians and interquartile ranges for continuous variables. GraphPad Prism 7.0 was used for plotting graphs and statistical analysis.

## **Results**

#### **Patient characteristics**

We report eight patients (2 female, 6 male) critically ill with a confirmed diagnosis of COVID-19 that were admitted to our institution from March 10, 2020 to May 21, 2020 and received CP therapy. The median age was 57 (IQR, 48-69), the median time from onset of symptoms to admission was 6 days (IQR, 3.00-8.75) and the median length of stay 22.5 days (IQR, 18.25-29.00) (**Table 1**). The most common comorbidities present were overweight/obesity (87.5%), hypertension (50%), diabetes mellitus (25%) and smoking (12.5%). The most common symptoms on admission were fever (100%) and dyspnea (100%), followed by cough (87.5%) and myalgia/arthralgia (75%). Seven out of eight

patients (87.5%) received chloroquine/hydroxychloroquine, lopinavir/ritonavir, and azithromycin. Six patients (75%) received ceftaroline and 3 patients (37.5%) tocilizumab.

Table 1. Baseline clinical and demographic characteristics.

179

180

181

183	Variable	n = 8
184	Age, median (IQR), yr	57 (48-69)
	> <b>60</b> , No. (%)	3 (37.5)
185	Female, No. (%)	2 (25)
	Male, No. (%)	6 (75)
186	Time from onset to admission,	6 (3-8.75)
	median (IQR), days	
187	Length of stay, median (IQR), days	22.5 (18.25-29)
	Comorbidities, No. (%)	
188	Smoking	1 (12.5)
189	Hypertension	4 (50)
	Diabetes	2 (25)
190	Overweight/obesity	7 (87.5)
	Symptoms at admission, No. (%)	
191	Fever	8 (100)
	Nasal congestion	1 (12.5)
192	Headache	2 (25)
132	Cough	7 (87.5)
193	Sputum	2 (25)
	Odynophagia	3 (37.5)
194	Dyspnea	8 (100)
195	Myalgia/arthralgia	6 (75)
	Chills/diaphoresis	4 (50)
	Clinical parameters, median (IQR)	
196	Heart rate, bpm	100 (78.75-135)
407	Respiratory rate, rpm	25 (17.75-31.5)
197	Temperature, °C	37.85 (36.8-38.22)
400	SOFA, pts	2 (2-4.25)
198	<b>QSOFA</b> , pts	0.5 (0-1)
199	CURB65, pts	1 (0.25-1.75)
100	<b>PSI</b> , pts	78.5 (61.5-85.75)
200	Treatment, No. (%)	7 (87.5)
200	Chloroquine/Hydroxychloroquine	7 (87.5)
201	Lopinavir/Ritonavir	7 (87.5)
	Azithromycin	6 (75)
	Ceftaroline	3 (37.5)

Five patients (62.5%) were under mechanical ventilation and three patients (37.5%) high-flow oxygen therapy (**Table 2**). The median duration of ventilatory/oxygen therapy was 12.5 days (IQR, 7.50-14.75). Under ventilatory/oxygen support, the median SaO<sub>2</sub> was 90% (IQR, 82.50-94.25), the median FiO<sub>2</sub> was 40% (IQR, 36.25-47.50) and the median SaO<sub>2</sub>/FiO<sub>2</sub> ratio was 2.25 (IQR, 1.67-2.61). No adverse effects were observed.

#### Table 2. Baseline laboratory and respiratory parameters.

Laboratory parameters,	n = 8	
median (IQR)		
Hemoglobin, g/dL	13.85 (12.7-14.75)	
Platelets, x 10 <sup>3</sup> /μL	204.5 (193-234)	
Glucose, mg/dL	121 (86.5-142.75)	
AST, U/L	40.5 (23.5-45)	
ALT, U/L	45 (25.25-61.5)	
Total bilirubin, mg/dL	0.60 (0.3-0.9)	
Creatinine, mg/dL	0.9 (0.73-1.08)	
<b>BUN,</b> mg/dL	12.35 (8.75-16.45)	
<b>Sodium,</b> mEq/L	136.5 (134.25-140.5)	
Potassium, mEq/L	4.25 (3.8-4.65)	
Chloride, mEq/L	101.5 (98-107.07)	
Respiratory parameters		
Mechanical ventilation, No. (%)	5 (62.5)	
Mechanical ventilation, No. (%) High flow oxygen therapy, No. (%)	5 (62.5) 3 (37.5)	
High flow oxygen therapy, No. (%)	3 (37.5)	
High flow oxygen therapy, No. (%)  Duration of ventilatory/oxygen	3 (37.5)	
High flow oxygen therapy, No. (%)  Duration of ventilatory/oxygen therapy, median (IQR), days	3 (37.5) 12.5 (7.50-14.75)	

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

**Laboratory parameters** Seven out of eight patients (87.5%) showed lymphocytopenia on admission and showed a slight improvement after CP therapy (median,  $0.75 \times 10^3 / \mu L$  vs.  $0.83 \times 10^3 / \mu L$ ) (Fig 1). Three patients (37.5%) were found with leukocytosis on admission, and the leukocyte count increased after CP therapy (median, 7.40 x  $10^3$  / $\mu$ L vs. 11.70 x  $10^3$  / $\mu$ L). Other laboratory parameters used as markers of inflammation were found with mixed results. We observed a reduction of C-reactive protein (CRP) (median, 22.80 mg/dL vs. 1.63 mg/dL), and of procalcitonin (median, 0.27 ng/mL vs. 0.13 ng/mL) after CP therapy. On the other hand, an increase of IL-6 (median, 16.00 pg/mL vs. 65.79 pg/mL) and ferritin (median, 421.0 ng/mL vs. 919.0 ng/mL) was observed after CP therapy. Fig 1. Markers of inflammation before and after CP therapy. Dynamic changes of inflammation markers before and after CP therapy in all patients. Dotted horizontal lines represent reference value ranges. A reduction of injury markers was observed (Fig 2): High-Sensitivity Cardiac Troponin I (hs-cTnI) (median, 8.20 ng/L vs. 1.50 ng/L), Brain Natriuretic Peptide (BNP) (median, 50.50 pg/mL vs. 14.20 pg/mL) and Lactate Dehydrogenase (median, 368.0 U/L vs. 325.0 U/L) were lower after CP therapy. An increase of D-dimer was observed after CP therapy (median, 393 ng/mL vs. 900 ng/mL).

Fig 2. Markers of cellular injury before and after CP therapy.

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

Dynamic changes of cellular injury markers before and after CP therapy in all patients. Dotted horizontal lines represent reference value ranges. **Pulmonary infiltrates** A mild reduction of pulmonary infiltrates severity score by chest X-ray was observed (median, 6 vs 5). Representative chest x-ray images for two patients, along with the severity score, before and after CP therapy, are shown (Fig 3). Fig 3. Severity of chest x-ray pulmonary infiltrates before and after CP therapy. Dynamic changes of lung infiltrates on chest X-ray before and after CP therapy. A) Changes in lung infiltrates as assessed by a severity score, in all patients. **B)** Representative images of the chest X-ray of two patients before and after CP therapy. Viral load On a separate group of 44 patients (23 with mild/asymptomatic course, 21 with severe course) we observed an association between viral load and disease severity (Fig 4A). Patients with severe COVID-19, defined as requiring hospitalization, showed a higher viral load (log, median [IQR], 0.90 [0.30-1.34] vs. 1.67 [0.74-2.22], p < 0.05). This led us to question whether viral load could be associated with clinical course after CP therapy on COVID-19 patients with severe illness. A reduction of viral load was observed in the group of eight hospitalized patients with severe COVID-19 after CP therapy (log, median [IQR], 1.2 [0.70-2.20] vs. 0.25 [0.00-1.78]) (**Fig 4B**).

Fig 4. Viral load and COVID-19 disease severity.

A) Viral load in asymptomatic/mild cases vs. hospitalized patients with severe illness, in a

different study group. B) Dynamic changes of viral load determined before and after CP

therapy for all the original group patients.

# **Discussion**

The major findings of this paper are: first, it was safe to administer CP to COVID-19 patients with impending respiratory failure. Second, inflammatory and cellular injury markers showed a decreasing tendency following CP administration. Third, significant improvements were observed in pulmonary infiltrates. Fourth, sequential analysis of viral load in respiratory samples showed a progressive reduction over-time. And finally, all patients were discharged home. Taken together, these observations support the hypothesis of the effectiveness of CP for COVID-19 patients with impending respiratory failure. To our knowledge, this is the first reported experience in Mexico of CP use for patients with COVID-19 with impending respiratory failure.

Experience with CP therapy is vast, as it has been utilized since the early twentieth century. During the 1918 influenza virus pandemic, CP therapy was implemented and evidence suggests it had an impact reducing mortality (10,11). Moreover, the use of CP has been evaluated for the treatment of several viral illnesses, such as Influenza A (H1N1), SARS, MERS and Ebola (12–16), and has been associated to reductions in mortality. For newly emerging viral mediated diseases, such as COVID-19, with no objective treatments, it provides at least a reasonable and testable approach. Moreover, it has been considered a

lower cost alternative (4), and its use could be advantageous for developing countries, provided its efficacy is demonstrated by randomized controlled trials.

The primary hypothesis of the mechanism of action of CP therapy for COVID-19 focuses on the fact that recovered individuals have developed antibodies that can neutralize viral activity and therefore, accelerate the recovery process (5,10,17–19). But this topic has been revisited recently (5). The mechanisms of action of CP are, probably, more extensive and therefore, best described as those that may result from direct antiviral activity and those that result from immunomodulation (5).

The antiviral activity of CP, in general, is likely the result of the presence of neutralizing antibodies (NAbs) (10,18,20,21), and to our knowledge this is yet to be confirmed for COVID-19 (6). It is possible that the number of neutralizing antibodies produced during the infection, or administered with therapeutic intent, determines to some extent the disease severity and clinical outcomes.

But NAbs represent only a subset of all antibodies produced against the virus. The immunomodulatory effects of CP may result, in part, from antibodies that block the effect of autoantibodies, proinflammatory cytokines and complement activation (5). In the context of COVID-19, possible immunomodulatory effects of CP could be equally important. In this sense, COVD-19 infection is associated with a profound inflammatory response beyond the injury that results from viral cellular damage (22–27).

Various strategies directed at modulating the immune response are currently being used off-label or are being studied in clinical trials, but evidence in favor or against their use for COVID-19 is still insufficient (28). The most representative therapies that target immunomodulation are interleukin-1 (IL-1) and interleukin-6 (IL-6) inhibitors, others include interferons alfa and beta, and Janus Kinase (JAK) inhibitors. For example,

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

Tocizilumab, an IL-6 receptor antagonist already FDA approved for rheumatoid arthritis among other indications, has shown promising results for the treatment of COVID-19 in preliminary reports (29–31). In a recent, multicenter, randomized clinical trial, CP therapy for patients with severe COVID-19 was associated with antiviral activity, shown as a higher rate of negative SARS-CoV-2 PCR up to 72 hours later (6). The findings of our paper are consistent with this observation (**Figure 4B**). To understand this further, we compared viral loads among asymptomatic SARS-CoV-2 PCR positive patients vs. COVID-19 hospitalized patients (**Figure 4A**). We found a significant difference among said groups. Hospitalized patients had higher viral loads than asymptomatic ambulatory patients. This observation suggests, that at least at some point in the disease process, viral loads are associated with disease severity (32). Moreover, we observed a decreasing tendency for inflammatory markers and pulmonary infiltrates severity after CP therapy, consistent with previous reports (8). There are limitations to our present study. Patients were receiving standard care, which could interact with the course of illness or with CP therapy. Neutralizing antibodies were not determined. However, our preliminary results support the completion of randomized larger trials. In summary, the present study supports the observations of others and reaffirms the importance of conducting prospective clinical studies aimed to define not only the best timing and cohort of patients in which CP should be used, but also to improve our understanding of the mechanisms of action.

# **Abbreviations**

**COVID-19:** Coronavirus Disease 2019

**BNP:** Brain Natriuretic Peptide

**CP:** Convalescent Plasma

**hs-cTnI:** High-sensitivity Cardiac Troponin I

**IL-1:** Interleukin-1

**IL-6:** Interleukin-6

**JAK:** Janus Kinase

**LDH:** Lactate Dehydrogenase

**NAbs:** Neutralizing antibodies

**RT-PCR:** Reverse transcription polymerase chain reaction

**SARS-CoV-2:** Severe acute respiratory syndrome coronavirus 2

# References

- 1. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19)
- [Internet]. Our World in Data. 2020 [cited 2020 Jun 9]. Available from:
- 353 https://ourworldindata.org/coronavirus
- 2. Secretaría de Salud. Datos Abiertos Dirección General de Epidemiología [Internet].
- gob.mx. [cited 2020 Jun 9]. Available from:
- 356 http://www.gob.mx/salud/documentos/datos-abiertos-152127
- 357 3. OECD. Health equipment Hospital beds OECD Data [Internet]. [cited 2020 Jun 9].
- 358 Available from: http://data.oecd.org/healtheqt/hospital-beds.htm
- 4. World Health Organization. Use of convalescent whole blood or plasma collected from
- patients recovered from Ebola virus disease. WHO [Internet]. [cited 2020 Jun 9];
- 361 Available from: https://www.who.int/csr/resources/publications/ebola/convalescent-
- 362 treatment/en/
- 5. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et
- al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev.
- 365 2020 Jul;19(7):102554.
- 366 6. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma
- Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening
- 368 COVID-19: A Randomized Clinical Trial. JAMA. 2020 Jun 3;

- 369 7. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill
- Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Mar 27;
- 8. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma
- therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020 Apr
- 373 28;117(17):9490.
- 9. Wong HYF, Lam HYS, Fong AH-T, Leung ST, Chin TW-Y, Lo CSY, et al. Frequency
- and Distribution of Chest Radiographic Findings in COVID-19

  Positive
- 376 Patients. Radiology. 2020 Mar 27;201160.
- 10. Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. J
- 378 Clin Invest. 2020 Apr 1;130(4):1545–8.
- 11. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood
- products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med.
- 381 2006 Oct 17;145(8):599–609.
- 12. Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of convalescent
- plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005
- 384 Jan 1;24(1):44–6.
- 385 13. Yeh K-M, Chiueh T-S, Siu LK, Lin J-C, Chan PKS, Peng M-Y, et al. Experience of
- using convalescent plasma for severe acute respiratory syndrome among healthcare
- workers in a Taiwan hospital. J Antimicrob Chemother. 2005 Nov 1;56(5):919–22.
- 388 14. Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility of
- Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia -

- Volume 22, Number 9—September 2016 Emerging Infectious Diseases journal -
- 391 CDC. [cited 2020 Jun 10]; Available from: https://wwwnc.cdc.gov/eid/article/22/9/15-
- 392 1164\_article
- 15. Hung IF, To KK, Lee C-K, Lee K-L, Chan K, Yan W-W, et al. Convalescent plasma
- treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009
- 395 virus infection. Clin Infect Dis. 2011 Feb 15;52(4):447–56.
- 396 16. Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, et al. Evaluation
- of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra
- 398 Leone. J Infect. 2017;74(3):302–9.
- 399 17. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al.
- Deployment of convalescent plasma for the prevention and treatment of COVID-19. J
- 401 Clin Invest. 2020 01;130(6):2757–65.
- 402 18. Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran
- A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic
- review. J Med Virol. 2020 May 1;
- 405 19. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses
- to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications.
- 407 medRxiv. 2020 Apr 20;2020.03.30.20047365.
- 408 20. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, et al.
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the

- Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic
- 411 Review and Exploratory Meta-analysis. J Infect Dis. 2015 Jan 1;211(1):80–90.
- 21. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is
- sufficient to confer protection against infectious diseases by inactivating the inoculum.
- 414 J Infect Dis. 1995 Jun;171(6):1387–98.
- 415 22. Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, et al. Convalescent
- plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
- 417 Cochrane Database Syst Rev. 2020 14;5:CD013600.
- 418 23. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of
- 419 COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med.
- 420 2020;8(4):420–2.
- 421 24. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
- 422 infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020
- 423 15;395(10223):497–506.
- 424 25. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-
- 425 19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020
- 426 28;395(10229):1033–4.
- 427 26. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with
- 428 Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020 Mar 16;

- 429 27. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
- 430 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
- 431 study. Lancet. 2020 28;395(10229):1054–62.
- 432 28. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19)
- 433 Treatment Guidelines. National Institutes of Health [Internet]. [cited 2020 Jun 15];
- 434 Available from: https://www.covid19treatmentguidelines.nih.gov/
- 435 29. Tocilizumab improves significantly clinical outcomes of patients with moderate or
- severe COVID-19 pneumonia [Internet]. [cited 2020 Jun 17]. Available from:
- https://www.aphp.fr/contenu/tocilizumab-improves-significantly-clinical-outcomes-
- patients-moderate-or-severe-covid-19
- 439 30. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective
- open, single-arm multicentre study on off-label use of tocilizumab in patients with
- severe COVID-19. Clin Exp Rheumatol. 2020 Jun;38(3):529–32.
- 31. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe
- 443 COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020
- 444 19;117(20):10970–5.
- 32. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou O, et al. Viral load dynamics and disease
- severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-
- March 2020: retrospective cohort study. BMJ [Internet]. 2020 Apr 21 [cited 2020 Jun
- 448 17];369. Available from: https://www.bmj.com/content/369/bmj.m1443











